PHASE-II EVALUATION OF BISANTRENE IN REFRACTORY MULTIPLE-MYELOMA - A SOUTHWEST ONCOLOGY GROUP-STUDY

被引：0

作者：

DURIE, BGM

CROWLEY, J

COLTMAN, CA

CHAPMAN, RA

BALCERZK, SP

BONNET, JD

LIPSCHITZ, DA

STEPHENS, RL

CHESON, BD

机构：

[1] UNIV ARKANSAS MED SCI HOSP,LITTLE ROCK,AR 72205

[2] UNIV KANSAS,MED CTR,KANSAS CITY,KS 66103

[3] UNIV UTAH,MED CTR,SALT LAKE CITY,UT 84112

[4] UNIV ARIZONA,CTR CANC,TUCSON,AZ 85721

[5] SW ONCOL GRP,CTR STAT,SEATTLE,WA

[6] UNIV TEXAS,HLTH SCI CTR,SAN ANTONIO,TX 78284

[7] HENRY FORD HOSP,DETROIT,MI 48202

[8] OHIO STATE UNIV,CTR HLTH,COLUMBUS,OH 43210

[9] SCOTT & WHITE MEM HOSP & CLIN,TEMPLE,TX

来源：

INVESTIGATIONAL NEW DRUGS | 1991年 / 9卷 / 04期

关键词：

BISANTRENE; MYELOMA;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：329 / 331

页数：3

共 9 条

[1]

DURIE BGM, 1983, BLOOD, V61, P929

[2]

DURIE BGM, 1986, SEMIN ONCOL, V13, P300

[3] IMPROVED SURVIVAL DURATION WITH COMBINATION CHEMOTHERAPY INDUCTION FOR MULTIPLE-MYELOMA - A SOUTHWEST ONCOLOGY GROUP-STUDY [J].

DURIE, BGM ;

DIXON, DO ;

CARTER, S ;

STEPHENS, R ;

RIVKIN, S ;

BONNET, J ;

SALMON, SE ;

DABICH, L ;

FILES, JC ;

COSTANZI, JJ .

JOURNAL OF CLINICAL ONCOLOGY, 1986, 4 (08) :1227-1237

[4]

MACKEL C, 1986, CANCER TREAT REP, V70, P1037

[5]

OSBORNE CK, 1984, CANCER TREAT REP, V68, P357

[6]

SALMON SE, 1981, CANCER TREAT REP, V65, P1

[7]

VONHOFF DD, 1982, CANCER, V50, P696, DOI 10.1002/1097-0142(19820815)50:4<696::AID-CNCR2820500413>3.0.CO

[8]

2-0

[9]

YAP HY, 1983, CANCER RES, V43, P1402

← 1 →